Biopharmaceutical company.
Implementation of Affordable Care Act as it relates to a regulatory pathway for biosimilars.

H.R. 6: 21st Century Cures Act.

Education about the value of innovative new medicines. H.R.5278: PROMESA Act. Education and outreach about the competitive elements of the Medicare Part D drug benefit and opposition to legislation imposing Medicaid style manufacturer rebates in the program.  

2016 CMS proposed rule implementing a new Part B drug payment model.  

H.R.5122: To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
HCR - Health Issues NAT - Natural Resources MMM - Medicare/Medicaid
2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE
W STRATEGIES, LLC
1455 Pennsylvania Avenue, NW, Suite 400, Washington, DC, 20004, US
DARREN WILLCOX DARREN WILLCOX DARREN WILLCOX